EUDA: Powering digital asset adoption in wellness
A demographic wave is reshaping Asia: rapidly aging populations are set to drive multi-trillion-dollar demand for non-invasive, preventive, and longevity-focused healthcare. And one under-the-radar Singapore innovator may be building one of the region’s most comprehensive toolkits—from next-gen nutraceuticals and bioenergy therapies to stem-cell programs and emerging genetic-modulation technologies.
Now, EUDA is adding a new catalyst to this ecosystem: the QB utility token.
​
Rather than functioning as a simple rewards mechanism, the QB token transforms EUDA’s wellness network into a unified, digital-first engagement platform. Customers can earn and redeem QB across EUDA’s full suite of offerings—spanning Bioenergy Capsule sessions, EUDA Helixe supplements, and select stem-cell services—creating a closed-loop loyalty system that deepens retention and expands lifetime value.
​
By combining preventive healthcare with tokenized digital engagement, EUDA is positioning itself at the center of Asia’s longevity boom—where wellness, technology, and consumer incentives converge into a next-generation health ecosystem
Why the Market Set-Up Looks So
Compelling Right Now
Demographic Tailwind – By 2030, more than 550 million people in China and ASEAN will be over 60, driving a longevity market forecast to eclipse $2 trillion annually.
Regulatory Fast-Track – Singapore and Malaysia have introduced expedited pathways for wellness and cell-therapy products, shrinking go-to-market timelines.
Tech Convergence – Advances in CRISPR, stem-cell banking, and AI-driven diagnostics are converging, lowering costs and boosting efficacy—perfect timing for first movers.
DeFi Integration - The addition of QB coins to EUDA's platform provides enhanced utility across payments, rewards and access to EUDA's healthcare products and services.
EUDA Health Holdings Limited (EUDA)
Ticker / Exchange
EUDA / NASDAQ
Core Focus
Non-invasive, preventive longevity solutions
Headquarters
Singapore
Target Geography
Singapore, Malaysia, India and Mainland China
EUDA’s mission
is simple yet audacious
Transform the health and wellness landscape by leveraging cutting-edge technology to enhance non-invasive treatments and expand holistic healthcare access in Southeast Asia. The company offers a diverse portfolio of innovative non-invasive wellness products and services, including bioenergy capsules and stem cell therapies, marketed under the CK Health brand in Malaysia and Singapore.
EUDA Plans to Integrate QB Utility Token into Its Healthcare Ecosystem
1
Utility On Chain
Built on Binance Smart Chain, the QB utility token supports seamless swaps with USD1—an enterprise-grade stablecoin interoperable across leading blockchain networks, with planned expansion to Solana and TRON through Chainlink’s Cross-Chain Interoperability Protocol.
2
Digital Wealth Gateway
Customers earn QB tokens for verified purchases, authentic reviews, and unlock access to DeFi opportunities such as yield farming, staking, and lending. The token's listing on major exchanges will offer liquidity and the ability to swap or pair QB with leading stablecoins.
3
Digital Asset Treasury
EUDA also plans to hold QB as part of its digital asset treasury, supporting long-term financial flexibility and participation in blockchain innovation.
This Integration Strengthens EUDA's Ecosystem By Enabling:​​​
Greater user engagement through digital utilities
Enhanced transparency through on-chain verification​
A compliant alternative to traditional rewards mechanisms
Technological modernization without engaging in token issuance or speculation
EUDA will create a platform where QB can be used for payments, rewards, and access to EUDA’s healthcare products and services, as well as those of its partners in the region. This connection between healthcare and digital finance allows QB to serve as both a useful health care token and a gateway to decentralized finance, bringing real-world healthcare value into the digital asset world.
QB Will Increase Momentum Across EUDA's Four Flagship Growth Drivers
Euda Helixe Nutragenic Supplement
Euda Helixe is a next-generation immune health formula that modulates gene expression by activating beneficial genes while silencing harmful ones, leveraging cutting-edge epigenetic science. Each capsule delivers a curated blend of deer placenta, vitamin E, astaxanthin, marine collagen, sea-buckthorn oil, grape-seed oil, and New Zealand avocado oil for gene-activated metabolic enhancement, sustained energy, and collagen-based youthfulness. Management projects  500,000 bottles sold in the next 12 months, underscoring Euda Helixe’s potential as the cornerstone of EUDA’s precision-wellness portfolio.
​
Integration with QB/DeFi: High-margin product whose sales are promoted and reinforced through QB loyalty campaign.
Euda Bioenergy Capsules
Positioned as a non-invasive, full-body wellness system that brings together six complementary technologies in a single 50-minute session, the Bioenergy Capsule is designed to boost vitality, immunity, and cellular recovery through integrated light, frequency, thermal, and magnetic therapies. EUDA’s CK Health subsidiary aims to deploy 1,000+ capsules across Southeast Asia in 2025, creating a regional network that can deliver over 1 million treatment sessions annually. This hardware-as-wellness model provides recurring revenue while funnelling users toward EUDA’s higher-margin supplements and therapies.
​
Integration with QB/DeFi: Hardware-as-Wellness model generating recurring revenue and funnelling users (and their QB rewards) toward higher-margin therapies.
Stem-Cell Therapies & T-Cell Immunotherapy
Through commercial distribution agreements with Guangdong Cell Biotech, EUDA gains access to a repertoire of autologous stem-cell treatments already serviced by 37 treatment centers spanning China, Indonesia, and Cambodia. A subsequent deal with Shenzhen Inno Immune extends the portfolio to affordable T-cell immunotherapies retailing at USD8,000—a fraction of traditional costs—broadening their reach. These partnerships accelerate EUDA’s entry into regenerative medicine without heavy capex while positioning the company as a one-stop longevity platform.
​
Integration with QB/DeFi: QB builds a broader customer base for these advanced, high-value treatments, accelerating adoption in regenerative medicine.
CRISPR Gene Editing Platform
EUDA frames CRISPR not as another therapy but as a “genetic operating system” capable of precisely cutting out what no longer serves you and enhancing what does. The program targets aging-related genes to strengthen immunity, improve detox pathways, and mitigate inherited disease risks. By integrating CRISPR with its nutraceuticals and cell therapies, EUDA envisions a closed-loop longevity ecosystem—from molecular maintenance to cellular rejuvenation (stem cells) and finally DNA-level optimization (CRISPR)—unlocking multiple monetization tiers as regulatory frameworks evolve
​
Integration with QB/DeFi: The final, highest monetization tier in the closed-loop longevity ecosystem, unlocking future revenue streams as regulatory frameworks evolve.
Recent Milestones Building Real Momentum
​EUDA Plans to Integrate QB Utility Token into Its Healthcare Ecosystem
Announced on 8 Dec 2025, EUDA introduced a major step forward in its digital healthcare strategy with the integration of the QB utility token across its ecosystem.
Developed by a third party and expected to launch in January 2026, QB will be used for payments, rewards, and access to EUDA’s healthcare products and services, as well as offerings from its partner network across Asia. EUDA also intends to hold QB within its digital asset treasury as part of its broader approach to financial flexibility and participation in blockchain-driven innovation.
EUDA Health Holdings Limited Announces Execution of Securities Purchase Agreement
Announced on 5 Dec 2025, EUDA announced that it entered into a securities purchase agreement on November 26, 2025 with Streeterville Capital, LLC, a Utah limited liability company, for the sale of a convertible warrant (the “Warrant”) for an aggregate purchase price of US$100,000. The Warrant is exercisable for up to 2,000,000 newly issued EUDA ordinary shares (the “Warrant Shares”) at an exercise price of US$6.00 per share and is being offered pursuant to the Company’s effective shelf registration statement on Form F-3 (File No. 333-282723) and a related prospectus supplement.
EUDA isn’t just announcing bold ideas—it’s executing a roll-up strategy that will change the landscape for non-invasive healthcare across Southeast Asia.
Investment Thesis in One Sentence
Even a small foothold in Asia’s surging longevity market could dramatically revalue EUDA, especially as the QB-enabled digital rewards ecosystem deepens customer engagement and accelerates platform-wide growth.
Latest
News
SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based leading non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced its plans to create an integrated digital health and rewards platform which will use a utility cryptocurrency called QB. The QB coins are being developed by a third party, and are scheduled to be launched sometime in January 2026 for use in EUDA’s digital health and wellness ecosystem.
SINGAPORE, Dec. 05, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or “the Company”), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it entered into a securities purchase agreement on November 26, 2025 with Streeterville Capital, LLC, a Utah limited liability company, for the sale of a convertible warrant (the “Warrant”) for an aggregate purchase price of US$100,000. The Warrant is exercisable for up to 2,000,000 newly issued EUDA ordinary shares (the “Warrant Shares”) at an exercise price of US$6.00 per share and is being offered pursuant to the Company’s effective shelf registration statement on Form F-3 (File No. 333-282723) and a related prospectus supplement.
23 OCT 2025
EUDA Subsidiary CK Health Plus Expands into India in Strategic Partnership with SafeRock India
SINGAPORE, Oct. 23, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, CK Health Plus Sdn. Bhd. (“CK Health Plus”), will expand into the Indian market through a strategic master license and representative partnership with SafeRock India Private Limited (“SafeRock India”), a SafeRock India Private Limited leading systems integration and infrastructure solutions companies in India.
Seasoned Leadership Steering the Longevity Vision
EUDA’s executive bench blends decades of life-sciences expertise with hard-nosed operational know-how—an essential mix for scaling a multi-faceted wellness platform.
EUDA’s leadership combines deal velocity, scientific rigor, and financial discipline—the very attributes that can turn a diversified longevity toolkit into a dominant regional franchise.